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2013.01.0Abstract Background: PM RMS represents a diagnostic and therapeutic problem as it is less vis-
ible than other superﬁcial head and neck sites, and has tendency to local and intracranial extension.
Objectives: The aim of this work is to study the treatment outcome, overall survival (OS) and event
free survival (EFS) of pediatric PM RMS patients diagnosed and treated at the Children Cancer
Hospital-Egypt [CCHE-57357] during a 4 year period.
Methods: Retrospective review of charts of newly diagnosed pediatric PM RMS patients diagnosed
and treated in CCHE during the period between July 2007 and the end of June 2011.
Results: Forty-two pediatric patients with PM RMS with age ranging from 3 months to 17.7 years
(median 6.9 years) were studied. The follow up period ranged from 4 to 55 months with a median of
24.8 months.
Twenty-one patients [50%] were stage III, while 11 patients [26.1%] were stage IV.1201919.
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80 H.A. Rahman et al.The 3-year overall survival (OS) was 58.4 ± 8.9%. OS was 65.9 ± 10% for non metastatic tumors
while it was 35.8 ± 16.2% for the metastatic ones (p= 0.039).
The 3-year event-free survival (EFS) was 48 ± 8.6% for the whole group. The non-metastatic and
metastatic patients had 3-year EFS of 56.5 ± 9.7% and 24.9 ± 14.9% respectively. This difference
was not statistically signiﬁcant (p= 0.127).
Conclusion: PM RMS remains a diagnostic and therapeutic problem. Late presentation and
advanced local disease compromise treatment options and decrease OS and EFS.
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Rhabdomyosarcoma (RMS) – originating from the primitive
mesenchymal tissue – is the commonest pediatric soft-tissue
sarcoma, constituting 3–5% of childhood malignancies [1].
The head and neck region represents about 35% of RMS [1].
Parameningeal rhabdomyosarcomas (PM RMS) are tumors
arising from sites adjacent to the meninges (nasopharynx, mid-
dle ear, paranasal sinuses, infratemporal and pterygopalatine
fossa) and constitute half of all head and neck RMS cases
[2–4]. PM RMS represents a diagnostic and therapeutic prob-
lem as it is less visible than superﬁcial head and neck sites, and
has a tendency of invasion of critical anatomic structures.
The outcome of PM RMS is still unsatisfactory compared
to other sites, necessitating a more aggressive therapy [6–8],
mostly due to delay in diagnosis [1], tumor tendency to intra-
cranial spread [5] and increased local recurrence [5–10].
The current standard treatment for RMS consists of a mul-
timodal therapy involving chemotherapy, radiotherapy and
surgery [11]. On the surgical level, PM RMS represents an
obstacle. Radical surgical approach is not feasible because of
the vital structures involved, and the likelihood for major cos-
metic consequences [12].
Radiotherapy – known to play an important part – is
needed for satisfactory local control, and has especially bene-
ﬁted from the new imaging tools, which enable a better target
ﬁeld design [13].
The aim of this work is to study the treatment outcome,
overall survival (OS) and event free survival (EFS) of pediatric
PM RMS patients diagnosed and treated at the Children Can-
cer Hospital-Egypt [CCHE-57357] during a 4 year period
(2007–2011).
Patients and methods
A retrospective review of charts of newly diagnosed pediatric
PM RMS patients diagnosed and treated in CCHE during
the period between July 2007 and the end of June 2011. All pa-
tients were followed up till the end of March 2012.
Patients were included in the study if they fulﬁlled the fol-
lowing criteria: (a) previously untreated, (b) below 18 years,
(c) conﬁrmed tissue biopsy in the parameningeal site and (d)
signed an informed consent.
Pretreatment investigations
A- Complete physical examination including: Weight, height
and surface area, site and clinical extent of the primary
tumor and regional lymph node enlargement.B- Laboratory investigations: Complete blood picture, liver
and kidney function tests, serum electrolytes. Bone mar-
row aspirate and biopsy and cerebrospinal ﬂuid analysis.
C- Radiological investigations:
1. Primary site: Magnetic Resonance Imaging.
2. Metastatic work up: CT scan of the chest and abdo-
men, isotopic bone scan.Histological categorization was based on pediatric interna-
tional classiﬁcation of rhabdomyosarcoma.
Deﬁnition of parameningeal sites
1. Middle ear: Medial to or extends through the tympanic
membrane and appears to be arising in the ear canal.
2. Nasal cavity and paranasal sinuses: maxillary, ethmoid, and
sphenoid sinus.
3. Nasopharynx: Bounded anteriorly by the back of the nasal
septum, superiorly by the sphenoid sinus, inferiorly by a
level corresponding to the soft palate, and laterally and pos-
teriorly by the pharyngeal walls.
4. Infratemporal fossa/pterygopalatine and parapharyngeal
area: Tissues bounded laterally by the medial lobe of the
parotid gland and medially by the pharynx that may extend
through the parotid gland and present as a mass in
the cheek. The superior boundary of this tissue volume
is the base of the skull just under the temporal lobe, hence
the term ‘‘infratemporal’’.Pretreatment staging
Patients were assigned according to the clinical TNM pretreat-
ment staging system based on site, size, clinical regional nodal
status and distant spread, using preoperative imaging and
physical ﬁndings:
Tumor: T)1 – conﬁned to anatomic site of origin, T)2 –
extension and/or ﬁxative to surrounding tissue.
a. 65 cm in diameter in size.
b. 5 cm in diameter in size.
Regional Nodes:
N0 regional nodes not clinically involved.
N1 regional nodes clinically involved by neoplasm.
Nx clinical status of regional nodes unknown.
Metastasis: M0 no distant metastasis, M1 metastasis
present.
Table 1 details the TNM pre-treatment staging
classiﬁcation.
Table 1 TNM Pre-treatment staging classiﬁcation.
Stage Sites T Size N M
1 Orbit T1 or a or N0 or M0
Head & neck (excluding parameningeal) T2 b N1 or
GU-non-bladder/non-prostate Nx
Biliary tract
2 Bladder/prostate T1 or a N0 or M0
Extremity, cranial T2 Nx
Parameningeal, other (includes trunk, -retroperitoneum, etc.)
(excludes biliary tract)
3 Bladder/Prostate T1 or a N1 M0
Extremity, cranial T2 b N0 or M0
Parameningeal, other (includes trunk, retroperitoneum, etc.) N1 or
(excludes biliary tract) Nx
4 All T1 or T2 a or b a or b N0 or N1 M1
Figure 1 Chemotherapy protocol.
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It was given according to the IRS IVth study 28 (Fig. 1).
It consisted of alternating doses of multi-agent chemother-
apy VAC every 21 days with weekly vincristine. Doses of che-
motherapy were:
- Vincristine (VCR); 1.5 mg/m2 IV push.
- Actinomycin (DACT); 1.35 mg/m2 IV push.- Cyclophosphamide (CTX); 1.5 mg/m2 at weeks 0 and 3 to
be increased to 1.8 gm/m2 if tolerated, given IV infusion
over 2 h with MESNA and IV ﬂuids.
Radiotherapy
Patients with parameningeal tumors who had erosion of the
base of the skull and/or cranial nerve palsy without evidence
Table 2 Clinical and epidemiologic characteristics of the studied patients.
Total number of patients (n= 42) Percentage
Sex
Male 25 59.5
Female 17 40.5
Pathology
Embryonal 31 73.8
Alveolar 7 16.7
Anaplastic 4 9.5
Site
Nasopharyngeal 10 23.8
Maxillary 8 19.0
Parapharyngeal 7 16.6
Sphenoid 3 7.1
Petrous 3 7.1
Masticator 3 7.1
Middle ear 2 4.7
Ethmoid 2 4.7
Infratemporal 1 2.3
Pterygopalatine 1 2.3
Paranasal 1 2.3
Zygomatic 1 2.3
TNM staging
Stage II 10 23.8
Stage III 21 50.0
Stage IV 11 26.2
Clinical response
CR 26 61.9
NR 3 7.1
PD 13 31.0
Local control
Surgery 2 4.8
Radiotherapy 36 85.7
Surgery + radiotherapy 4 9.5
CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; R, relapse.
82 H.A. Rahman et al.of intracranial extension received radiotherapy to both the pri-
mary and metastatic sites at week 12. If patients had evidence
of intracranial extension and/or cranial nerve palsy, radiation
therapy was started at week 1 (Day 0).
Target volume deﬁnitions
CT-based planning techniques were used. All treatment plan-
ning was based upon the following target deﬁnitions. Treat-
ment was prescribed to the PTV, which was derived from the
GTV and CTV as follows:
Gross tumor volume (GTV): The volume occupied at diag-
nosis by a visible or palpable disease.
Clinical target volume (CTV): The GTV plus any sites that
warrant irradiation because of potential occult tumor
involvement.
The PTV is generated by adding a margin to the CTV in or-
der to compensate for variability in treatment setup, breathing,
or motion during treatment. This margin is 5 mm as per
department protocol for the head and neck.
All patients received radiotherapy to the primary and met-
astatic sites, with a total dose of 50.4 Gy in 28 fractions of
1.8 Gy delivered once a day, 5 days a week for all sites.Treatment technique
Volume-based (three-dimensional) planning was applied lead-
ing to a homogenous dose to PTV with a minimal dose to the
surrounding organs at risk, not exceeding the tolerance level of
any of them. Intensity modulated radiation therapy (IMRT)
was performed in most of the patients.
Evaluation criteria
Complete response (CR): Complete disappearance of the tu-
mor conﬁrmed at >4 weeks.
Partial response (PR): At least 64% decrease in volume
compared to the baseline.
Progressive disease (PD): At least 40% increase in tumor
volume compared to the smallest measurement obtained since
the beginning of the therapy.
Stable Disease (SD): Neither sufﬁcient shrinkage to qualify
for PR nor sufﬁcient increase to qualify for PD taking as ref-
erence the smallest disease measurement since the treatment
started.
Relapse/recurrence(R): appearance of new lesions or reap-
pearance of old lesions for patients in CR.
Table 3 Initial site and TNM staging on treatment outcome of the 42 studied patients.
Serial number Site T N M Stage Metastatic site Tumor response
1 Maxillary 2b N0 M0 3 CR
2 Zygomatic 1a N0 M0 2 CR
3 Temporal 2b N0 M0 3 CR
4 Middle ear 2a N0 M0 2 CR
5 Maxillary 2b N0 M0 3 CR
6 Nasopharyngeal 1a N0 M0 2 CR
7 Nasopharyngeal 2b N0 M0 3 CR
8 Ptrygopalatine fossa 1a N1 M0 3 CR
9 Sphenoid 2a N1 M0 3 CR
10 Maxillary 2a N0 M0 2 CR
11 Maxillary 2b N0 M0 3 CR
12 Petrous 2b N1 M1 4 Lung CR
13 Parapharyngeal 2b N0 M0 3 CR
14 Maxillary 2a N0 M0 2 CR
15 Infratemporal 2b N0 M0 3 CR
16 Maxillary 1a N0 M0 2 CR
17 Nasopharyngeal 1a N0 M0 2 CR
18 Nasopharyngeal 2a N1 M1 4 Bone CR
19 Nasopharyngeal 2a N1 M0 3 CR
20 Nasopharyngeal 2b N1 M0 3 CR
21 Nasopharyngeal 2b N1 M1 4 Lung CR
22 Sphenoid 2b N0 M0 3 CR
23 Sphenoid 2b N0 M0 3 CR
24 Ethmoid 2a N0 M0 2 CR
25 Nasopharyngeal 1a N1 M0 3 CR
26 Mastecator 2b N1 M1 4 Bone & BM CR
27 Nasopharyngeal 2b N0 M1 4 Lung PD
28 Parapharyngeal 2a N0 M0 2 PD
29 Middle ear 1a N0 M1 4 Lung PD
30 Mastecator 2b N0 M0 3 PD
31 Ethmoid 2b N0 M1 4 Bone PD
32 Parapharyngeal 2a N0 M0 2 NR
33 Parapharyngeal 2b N1 M1 4 Bone & lung PD
34 Parapharyngeal 2b N1 M0 3 NR
35 Mastecator 2b N1 M1 4 Lung PD
36 Nasopharyngeal 2b N0 M0 3 NR
37 Maxillary 2b N1 M1 4 Lung PD
38 Petrous 2a N1 M1 4 Lung PD
39 Maxillary 2b N0 M0 3 PD
40 Petrous 1a N1 M0 3 PD
41 Parapharyngeal 2b N0 M0 3 PD
42 Parapharyngeal 2b N1 M0 3 CR
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Event-free survival (EFS) and overall survival (OS) were esti-
mated according to the Kaplan–Meier method. To study
EFS, patients were evaluated from the date of diagnosis to
the date of disease progression, recurrence, or death due to
any cause. For OS, patients were evaluated from diagnosis
to death. The time scale extended as far as the most recent fol-
low up if none of these endpoints were reached. To establish
the potential value of prognostic factors, survival curves for
different subgroups of patients were compared using the log
rank test.
Results
Out of 148 new RMS patients presented during the study per-
iod (2007–2011), 42 had PM RMS representing 28.3% of the
whole RMS patients.The age of the patients ranged from 3 months to 17.7 years
(median 6.9). They were 25 males and 17 females with a male
to female ratio of 1.3:1. Follow up period ranged from 4 to
55 months with a median of 24.8 months.
Table 2 shows the epidemiologic criteria and clinical re-
sponse of the patients to primary chemotherapy.
Twenty-one patients [50%] were stage III, while 11 patients
[26.1%] were stage IV, and 10 patients [23.8%] were stage II.
The most common tumor site was nasopharyngeal, followed
by maxillary and parapharyngeal mass. The most common
metastatic site was the lungs (7/11–63.6%), followed by bone
(2/11–18.2%) and multiple sites [bone + bone mar-
row + lung] in (2/11–18.2%). Table 3 shows the initial site
and TNM staging of the 42 studied patients.
Fourteen patients died during the study period, and one
patient lost follow up. The cause of death was the progressive
disease while on chemotherapy in 11/14 [78.5%] and septice-
mia during salvage chemotherapy in 3/14 [21.5%] of the
patients.
Figure 2 Overall survival (OS) of all parameningeal RMS cases.
Figure 3 Overall survival (OS) by metastasis at presentation in
parameningeal RMS.
Figure 4 Event free survival (EFS) of all parameningeal RMS
cases.
Figure 5 Event free survival (EFS) by metastasis at presentation
in parameningeal RMS.
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The OS was 65.9 ± 10% for non metastatic tumors and
35.8 ± 16.2% for metastatic ones (p= 0.039) (Fig. 3).
Event free survival (EFS) was 48 ± 8.6% for the whole
group at the same period (Fig. 4). The non-metastatic patients
had a higher 3-year EFS than metastatic ones [56.5 ± 9.7%
versus 24.9 ± 14.9%]. However, this difference did not reach
to the level of statistical signiﬁcance (p= 0. 127) (Fig. 5).
Discussion
PM RMS outcome remains a real problem with much inferior
results than other sites. The aim of our work is to study the
epidemiologic data, treatment outcome, OS and EFS of newly
diagnosed, pediatric PM RMS patients treated at the Chil-
dren’s Cancer Hospital Egypt 57357 (CCHE) during a 4 year
period.Age of our patients at presentation ranged from 3 months
to 17.7 years (mean 9.1, median 6.9 ± 4.3 years). Our results
are in concordance with many other authors, who reported a
median age of 7.7 years (range 0.3–19.9) [14]. Most of the pa-
tients (67–87%) were below 14 years [3–15]. Similarly, Douglas
et al. reported a median age of 8.5 years (range 1.5–19 years)
[15–16]. This appears coherent in RMS, a disease being consid-
ered the most common soft tissue sarcoma of early childhood
[17]. Moreover, we have noticed a slight male predominance,
as our M:F ratio was 1.3: 1. This male predominance was con-
ﬁrmed by Douglas et al., who detected a male to female ratio
of 1.6:1 [16]. Other authors also notiﬁed that 58–63% of their
patients were males [3,14,18].
In our study, site was not easy to establish because more
than one of the parameningeal sites were involved, and most
of the patients presented with a locally advanced tumor. The
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lowed by maxillary and parapharyngeal masses. Similar results
were shown by many other authors, as their main tumor site in
nasopharynx followed by parapharyngeal and maxillary sinus
[16]. Contrarily, Cristina et al. showed the most frequent tu-
mor site is the paranasal sinuses, followed by pterygopalatine
and infratemporal fossa [19].
Half of our patients presented in stage III while 23.8% of
patients had stage II and 26.2% had stage IV. These ﬁgures
were in concordance with what is described by other authors
as PM RMS which is mainly a stage III followed by stage
IV disease. Such advanced tumor stage may be explained by
being less visible than the superﬁcial head and neck sites [20],
and the tendency to leptomeningeal progression [5].
The embryonal pathological subtype predominated in our
patients (73.8%). Similar results were also reported in the liter-
ature representing 50–70% of patients [3,19,21,22].
PM RMS treatment has undergone breakthrough changes
since the start of the International Rhabdomyosarcoma Study
Group trials [IRSG] 40 years ago [23,24]. The IRS-IV pilot
study [25] showed the VAC therapy (Vincristine, Actinomycin
D and Cyclophosphamide) is as equally effective as other che-
motherapeutic regimens as VAI (Vincristine, Actinomycin D,
Ifosfamide) or VEI (Vincristine, Ifosfamide, Etoposide).
In the present study, 62% of our patients achieved CR and
remained in continuous complete remission (CCR) by the end
of the study period, while the rest (38%) had no response or
progressed on 1st line regimen. Of 424 PM-RMS patients en-
rolled on IRSG protocols from 1984 to 1995, 84% achieved re-
sponse including all tumor sites. Local failure was the most
common site for unresected non metastatic RMS in IRS III
and IV (15–17%) [26–29]. In a study conducted by Smith
et al. assessing intensive chemotherapeutic regimen with de-
layed local radiotherapy at week 21, 38% of their patients
achieved complete response while 62% had partial response
[30]. In another study including 26 pediatric patients of group
III PM-RMS, the radiographic response following neo-adju-
vant chemotherapy till week 12 was CR in 22% and PR in
74%. The authors concluded that radiotherapy could be de-
layed to allow for better local regional control [16]. Similar reg-
imen was also applied in another study to 14 PM-RMS
patients; nobody showed progression during induction [16,31].
In our series disease progression was the cause of death in
26.1%, while 7.1% of our patients died due to septicemia fol-
lowing salvage chemotherapy. All the patients were stages III
or IV disease.
The present study results are worse than those reported in
similar studies. Out of 13 patients included in Smith et al.
study, 2 patients (15.3%) died from recurrent disease [30]. In
another study including 26 patients, four failures were de-
tected, all were relapsing evenly either as a local disease or dis-
tant metastasis, in addition to one patient who died from 2ry
leukemia (19.2%) [16].
At 36 months, OS in our group is 58.4% and that of EFS is
48%. These ﬁgures are again worse than those reported by
Maurer et al. as their overall survival was 69% [3]. In another
study, the OS was similar to that in the present study (60% at
5 years), but included all the sites of head and neck with multi
modality treatment [21]. Both tumor size and age of patients
were found to inﬂuence survival [21]. The prognosis of para-
meningeal RMS was the worst in a study where the OS was
even less to 27% at 5 years if no complete remission on chemo-therapy is reached [21]. Similar ﬁgures were obtained for the
OS at 5 and 10 years, and were 20.4% [18]. Maurer et al. re-
ported 5 years OS of 92% for orbital tumors, compared to
81% for nonparameningeal tumors and 69% in PM sites [3].Conclusion
PM RMS remains a diagnostic and therapeutic problem. Tu-
mor stage, size, and distant metastasis and response to chemo-
therapy remain the most important prognostic factors.
Multimodality chemotherapy is the main line of treatment,
but with a smaller role to surgery due to early intracranial
extension, and INVASION OF VITAL ORGANS. Late pre-
sentation and advanced local disease compromise treatment
options and decrease OS and EFS of our patients.References
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